Synopsis of recent research by authors named "ZhaoHang Wu"
- Zhaohang Wu's research prominently investigates the therapeutic potential of fibroblast growth factors (FGF21 and FGF18) across various pathological conditions, demonstrating FGF21's ability to ameliorate fibrotic disease and septic liver injury by inhibiting key signaling pathways.
- The studies reveal the mechanisms by which FGF21 and FGF18 operate, including the CK2α/GLI2 signaling axis and the USP16-mediated KEAP1/Nrf2 signaling pathway, highlighting their roles in regulating inflammation and injury responses.
- Additionally, Wu's work addresses diabetes-related complications, showing that inhibition of CK2α can enhance wound healing through endothelial cell proliferation, thus linking metabolic disorders with cellular repair mechanisms.
